BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC lessened its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 852,741 shares of the medical equipment provider's stock after selling 12,525 shares during the period. Geneva Capital Management LLC owned about 1.84% of BioLife Solutions worth $22,137,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of BLFS. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions in the third quarter worth $28,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions during the third quarter worth $57,000. Smartleaf Asset Management LLC boosted its stake in shares of BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after purchasing an additional 950 shares during the period. Finally, Summit Global Investments bought a new position in shares of BioLife Solutions in the third quarter worth about $228,000. Institutional investors own 93.24% of the company's stock.

Insider Buying and Selling

In other news, EVP Aby J. Mathew sold 7,604 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the transaction, the executive vice president now directly owns 276,315 shares of the company's stock, valued at approximately $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares of the company's stock, valued at $3,290,468.58. The trade was a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,978 shares of company stock worth $322,724 in the last 90 days. 2.20% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Benchmark reiterated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. HC Wainwright lifted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Northland Securities lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. Finally, Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus target price of $29.86.

BioLife Solutions Stock Down 3.8 %

NASDAQ:BLFS traded down $0.97 during trading hours on Monday, reaching $24.86. The company's stock had a trading volume of 648,726 shares, compared to its average volume of 350,114. The stock has a 50 day moving average price of $26.65 and a two-hundred day moving average price of $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market capitalization of $1.17 billion, a P/E ratio of -23.45 and a beta of 2.04. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period in the previous year, the company posted ($0.21) EPS. Equities analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.